Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Retrieved on:
Sunday, September 12, 2021
An updated and expanded data set will be presented at the ESMO Annual Congress taking place virtually on September 16-21, 2021.
Key Points:
- An updated and expanded data set will be presented at the ESMO Annual Congress taking place virtually on September 16-21, 2021.
- The confirmed objective response rate was 68.2% and the disease control rate was 90.9% in 22 HER2-positive response-evaluable patients.
- Were looking forward to presenting at the Congress the full updated data, which further support zanidatamabs potential as the new foundational HER2-targeted therapy.
- Dr. Ku and members of Zymeworks executive team will be available to answer questions at the conclusion of the call.